Genentech and Roche Break Ground on State-of-the-Art Manufacturing Facility in Holly Springs, North Carolina
Genentech's Susvimo Maintains Vision Over Five Years With Two Refills Per Year in People With Wet Age-Related Macular Degeneration
Genentech's Tecentriq Combined with Lurbinectedin Shows Significant Survival Benefit in Extensive-Stage Small Cell Lung Cancer
New Data Show Genentech's Itovebi Significantly Extended Survival in a Certain Type of HR-positive Advanced Breast Cancer
Ten-Year APHINITY Data Show Genentech's Perjeta-based Regimen Reduced the Risk of Death by 17% in HER2-Positive Early-Stage Breast Cancer
FDA Accepts Supplemental Biologics License Application for Genentech's Gazyva for the Treatment of Lupus Nephritis
Five-year Data for Genentech's Evrysdi Show the Majority of Treated Children With a Severe Form of Spinal Muscular Atrophy Achieved or Maintained the Ability to Sit, Stand or Walk
FDA Grants Priority Review to Genentech's Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer With a PIK3CA Mutation
Roche and Hitachi High-Tech extend their 46-year partnership, paving the way for further breakthroughs in diagnostic testing
FDA Grants Breakthrough Therapy Designation to Genentech's Inavolisib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with a PIK3CA Mutation
Finlay Minerals completes Field Work on Newly Identified Geophysical Targets on the SAY and JJB Properties
Aventis Energy Confirms Strong Radioactivity During Successful Exploration Program at the Corvo Uranium Project
Stallion Uranium Appoints Peter Dembicki to Board of Directors, Initiates Haystack Intelligent Targeting Study
